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Background Previous studies suggest an association between obesity and oe-
sophageal (OA) and oesophagogastric junction adenocarcinomas
(OGJA). However, these studies have been limited in their ability
to assess whether the effects of obesity vary by gender or by the
presence of gastro-oesophageal reflux (GERD) symptoms.
Methods Individual participant data from 12 epidemiological studies
(8 North American, 3 European and 1 Australian) comprising
1997 OA cases, 1900 OGJA cases and 11 159 control subjects were
pooled. Logistic regression was used to estimate study-specific odds
ratios (ORs) and 95% confidence intervals (CIs) for the association
between body mass index (BMI, kg/m2) and the risk of OA and
OGJA. Random-effects meta-analysis was used to combine these
ORs. We also investigated effect modification and synergistic inter-
action of BMI with GERD symptoms and gender.
Results The association of OA and OGJA increased directly with increasing
BMI (P for trend <0.001). Compared with individuals with a BMI
<25, BMI 540 was associated with both OA (OR 4.76, 95% CI 2.96–
7.66) and OGJA (OR 3.07, 95% CI 1.89–4.99). These associations were
similar when stratified by gender and GERD symptoms. There was
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which
permits non-commercial reuse, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com
Published by Oxford University Press on behalf of the International Epidemiological Association
 The Author 2012; all rights reserved. Advance Access publication 12 November 2012
International Journal of Epidemiology 2012;41:1706–1718
doi:10.1093/ije/dys176
1706
evidence for synergistic interaction between BMI and GERD symp-
toms in relation to OA/OGJA risk.
Conclusions These data indicate that BMI is directly associated with OA and
OGJA risk in both men and women and in those with and without
GERD symptoms. Disentangling the relationship between BMI and
GERD will be important for understanding preventive efforts for OA
and OGJA.
Keywords Oesophageal neoplasms, aetiology, risk factors, gastro-oesophageal
reflux, obesity, oesophagogastric junction
Background
The incidence of adenocarcinomas of the oesophagus
(OA) has increased 4650% in the USA over the past
35 years, the steepest increase of any cancer during
this period.1,2 To a lesser extent, the incidence of the
anatomically linked oesophagogastric junction adeno-
carcinoma (OGJA) has also risen.3 Five-year survival
for these cancers continues to be low despite improve-
ments in treatment modalities and supportive care.4,5
Over the past 2 decades, research has focused on
identifying risk factors for OA and OGJA, with an
ultimate goal of elucidating a strategy to reduce inci-
dence and mortality from these cancers. Any poten-
tially effective prevention programme will need to
take into consideration that the incidence varies dra-
matically by race and gender, with White men com-
prising 80% of individuals with OA and OGJA.6,7
Consistently documented risk factors for these
tumours include symptoms of gastro-oesophageal
reflux (GERD)8,9 and male gender.6 Increasing body
mass index (BMI) has also been associated with OA
and OGJA tumours (reviewed in the article by
Lagergren10), and perhaps GERD (reviewed in the art-
icles by El-Serag11 and Friedenberg12). Higher BMI
(kg/m2) may directly increase the propensity for
GERD13,14; android obesity may increase intra-
abdominal pressure, distort the lower oesophageal
sphincter and increase the likelihood of hiatal
hernia. Several recent lines of evidence also suggest
that BMI may increase the risk of OA, its precursor
lesion Barrett’s oesophagus, and OGJA independently
of GERD.13–19 Potential indirect mechanisms of these
associations include the idea that differences in adi-
pose distribution between men and women may
partly explain the much higher incidence of these
cancers in men.20,21 Men typically acquire android
fat patterns, characterized by central abdominal fat
deposits, whereas women typically develop gynoid
forms, with fat deposits on the hips and thighs21,22;
android (visceral) fat is known to be more metabol-
ically active20 relative to gynoid.23,24 Disentangling
these relationships will be important for primary
prevention of these tumours, but so far these efforts
have been limited by small case numbers of partici-
pants in individual studies. The International Barrett’s
and Esophageal Adenocarcinoma Consortium
(BEACON, http://beacon.tlvnet.net/) provided data
from 12 studies to assess the effect of increasing
BMI on OA and OGJA risk. The large size of the con-
sortium also enabled the assessment of potential
effect modification by GERD and gender.
Methods
Study population
This combined analysis included participants in OA and
OGJA studies who contributed their data to the
International BEACON. BEACON was formed in 2005
by an international group of investigators in collabor-
ation with the US National Cancer Institute. The con-
sortium consists of completed or ongoing case–control
and cohort studies of OA, OGJA and/or Barrett’s
oesophagus and has a primary aim to provide an open
scientific forum for epidemiological research into
the aetiology and prevention of these diseases by facil-
itating the sharing of data across population-based stu-
dies. Therefore, rather than relying on a meta-analytical
approach with published risk estimates, which often
have different variable definitions and statistical
models, BEACON enables pooled analyses of individual
participant data from population-based studies using
a standard model, after harmonization of variable def-
initions and common confounders.
Data from 10 case–control studies, conducted be-
tween 1988 and 2005, and two cohort studies, with
recruitment between 1964 and 1996, were available
through BEACON at the time of analysis. Of the 12
studies, 8 were conducted in North America,25–31 3 in
Europe18,32,33 and 1 in Australia.19 Detailed descrip-
tions of case ascertainment procedures can be found
in study-specific publications.18,19,23,25–30,32–34
Cases
The main outcomes were (i) OA, (ii) OGJA and (iii)
OA and OGJA grouped together (all adenocarcin-
omas). For each study, determination of case partici-
pant eligibility was based on pathology reports and/or
review of medical records. In both cases, determin-
ation of histology and site of tumour origin of OA
vs OGJA was made based on radiology, surgery, or
endoscopy reports and review of pathology or reports.
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Control subjects
Control subjects were identified from the populations
from which the cases arose. For the cohort studies, a
nested case–control approach was used, where a
random sample of control subjects for each case was
selected. The case–control ratio was 1:4 for the
National Institutes of Health–American Association
of Retired Persons (formerly known as American
Association of Retired Persons) cohort study and 1:8
for the Kaiser Permanente cohort.27
Inclusion criteria and the pooling strategy have
been described elsewhere.35 In total, 4214 cases and
13 750 control subjects were available for pooling.
Cases included 2138 OAs and 2076 OGJAs. We excluded
participants for whom either height or weight was
missing (422 control subjects 49 OA, 45 OGJA). The
analysis was limited to non-Hispanic White participants
because the BEACON pooled data set had too few
African American (12 OA, 35 OGJA, 1226 control sub-
jects), Hispanic (55 OA, 48 OGJA, 442 control subjects)
or other-ethnicity participants (23 OA, 45 OGJA, 449
control subjects) for meaningful analysis. In addition,
we excluded individuals for whom race was unknown
(52 control subjects, 2 OA, 3 OGJA). Analyses were thus
based on 3897 cases (1997 OA, 1900 OGJA) and 11 159
control subjects.
In Table 1, we present basic descriptive characteris-
tics of the case and control populations for each
study. The conduct of individual studies and contri-
bution of data for consortial analyses in BEACON
were approved by the relevant institutional review
or research ethics boards for each study.
Study variables
BMI was based on self-reported adult height and
weight for all studies, although the exposure date in
relation to cancer diagnosis varied across studies.
Consequently, we used usual adult weight.15,28,30,34
If usual adult weight was unavailable, we used
weight 1 year,19,26,29 5 years32 or 20 years before inter-
view.18 One study ascertained weight at age 20 years
and maximum adult weight (excluding pregnancies),
for which we used the latter weight, assuming it more
accurately reflected usual adult weight.28 For the two
nested case–control studies, we used weight at cohort
entry.23,27 BMI was categorized into an ordinal vari-
able with five groups based on WHO criteria36: BMI
<25, BMI 25–29.9, BMI 30–34.9, BMI 35–39.9 and
BMI 540. Additionally, we defined a combined
obese group (BMI 530). Fewer than 1% of partici-
pants had a BMI <19, and these were included in the
referent category of BMI <25.
GERD symptoms, where available,19,25,26,32 were
defined as a history of reflux or heartburn 1 year be-
fore diagnosis for cases and 1 year before interview
for control subjects. Heartburn symptoms solicited
included ‘burning or aching pain behind the breast-
bone not due to heart problems’. Reflux symptoms
solicited included ‘sour taste from acid, bile or con-
tents of the stomach’.
Other covariables included in analyses were age (cate-
gorized as <50, 50–59, 60–69 and 570 years), gender,
education (less than high school, high school or more),
cigarette smoking (categorized as <15, 15 to <30, 30 to
<45 and 545 pack-years derived from dividing the
number of cigarettes smoked by 20 and multiplying by
the total number of years smoked), regular alcohol
consumption (yes/no) and, where available,15,18,26,32
Helicobacter pylori colonization (yes/no).
Statistical analyses
Using each study’s individual-level data and covari-
ates, we estimated study-specific odds ratios (ORs)
and 95% confidence intervals (95% CIs) for the asso-
ciation between BMI categories and adenocarcinoma
outcomes using logistic regression models. We also
estimated ORs and 95% CIs per unit increase in
BMI as a continuous covariate. All models were
adjusted for age, gender, education, cigarette smok-
ing, GERD (where available) and study-specific vari-
ables, such as study centre,35 as applicable.
Study-specific estimates were subsequently combined
using random-effects meta-analytic models. The re-
sults from fixed-effects models were similar; however,
we believe that random-effects models are more ap-
propriate for the current analyses.37 To estimate het-
erogeneity, we computed the I2 statistic.38 The I2
statistic ranges from 0 to 100%, where I2¼ 0 indicates
no observed heterogeneity and larger values indicate
increasing heterogeneity.
We also investigated the relationship between BMI
and cancer using spline models39 to plot the relationship
on a continuous scale. Restricted cubic spline models
allow for easy visualization of non-linear relationships
between an exposure and an outcome40,41—in this case,
BMI and OA/OGJA. These analyses were adjusted for
age (categorical), gender, pack-years of cigarette smok-
ing (categorical), education (harmonized, dichotom-
ous: less than high school, high school or more) and
study site/centre (categorical) using the pooled data
set of individual patient data. Results from spline
models were plotted using a linear scale on the x-axis
for BMI and a logarithmic (base 10) scale on the y-axis
for the OR. Plots were constructed for OA and OGJA
overall and also for subgroups defined by gender and
GERD symptoms.
We assessed whether there was evidence for effect
modification—i.e. whether the effect of single expos-
ure (BMI) on cancer risk (OA/OGJA) varied over
strata of a second variable (an effect modifier).42–44
The variables, age, gender and GERD symptoms were
tested as potential effect modifiers of the association
between BMI and cancer. We evaluated the strength
of potential effect modification by addition of product
terms to study-specific logistic regression models fol-
lowed by random-effects meta-analysis.
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We also assessed whether there was evidence of
interaction (synergism or departure from
additivity)42–44 i.e. whether the joint effect of two
exposures (BMI and another) had greater effects on
the risk of OA and OGJA than would be expected
from the independent effects of each exposure.
Dichotomous variables tested for departure from addi-
tivity with BMI (dichotomized at <27.5 and 527.5)
were cigarette smoking, gender, alcohol, GERD symp-
toms and H. pylori colonization. For each combination
of variables, we generated four exposure categories.
These variables were modelled in the pooled data
set using logistic regression adjusted for age (categor-
ical), gender, BMI (continuous), heartburn or reflux
(if unavailable for a study, all individuals were
recoded to a missing category and were excluded
from the heartburn/reflux/heartburn-or-reflux–BMI
interaction models), education (harmonized, dichot-
omous: less than high school, high school or more)
and study site/centre (categorical). The output from
these models was used to estimate three interaction
statistics: interaction contrast ratio (ICR), attributable
proportion (AP) and synergy index (S). When the ICR
and AP 6¼ 0, and S 6¼ 1, there is evidence for departure
from additivity (interaction). ICR is the excess risk
due to interaction relative to the risk without either
exposure. AP is the proportion of disease attributable
to interaction among individuals with both exposures.
S is the ratio of the observed excess risk in individuals
exposed to both factors relative to the expected excess
risk assuming that both exposures are independent
risk factors (i.e. under the assumption of no additive
interaction). CIs for these metrics were estimated
using the delta method.45 All analyses were con-
ducted using STATA software version 11 (StataCorp
LP, College Station, TX).
Results
Descriptive characteristics of case and control groups
by study are shown in Table 1. The number of cases
varied between studies from 72 to 747, and the mean
ages were generally 63–65 years, although the age
was much younger in the Kaiser Permanente
Multiphasic Health Check-up Study because of its
design (cohort). The UK study was of women only,
and the Population Health Study was of men only,
but all other studies were composed of, on average,
86% men and 14% women. The mean BMI for cases
was generally higher than that for control subjects
with overall means being 27.2 and 26.0, respectively.
Table 2 shows adjusted summary ORs for the asso-
ciations between BMI and the risk of OA, OGJA and
all adenocarcinomas among men and women com-
bined. Compared with BMI <25, the increase in OA
risk in individuals with BMI 25–29.9 was 1.54 (95%
CI 1.26–1.88), a risk that increased to 42-fold in in-
dividuals with BMI 30–34.9 (OR 2.39, 95% CI
1.86–3.06) or BMI 35–39.9 (OR 2.79, 95% CI
1.89–4.12) (Table 2), and almost 5-fold in individuals
with BMI 540 (OR 4.76, 95% CI 2.96–7.66). The pat-
terns of association between BMI and these adenocar-
cinomas were similar in younger (465 years) and
older (465 years) individuals when stratified by age
at diagnosis (data not shown). These results were un-
altered when we repeated the analyses, adjusting for
GERD, in the five studies with GERD information
(data not shown). This monotonic increase in risk
was also observed when BMI was evaluated in rela-
tion to OGJA and all adenocarcinomas. The associ-
ations were slightly stronger with OA than OGJA.
Excluding individuals with potential cachexia (BMI
<18.5) had little effect on the estimates attained.
We evaluated the association between BMI and OA,
OGJA and all adenocarcinomas, stratified by GERD
symptoms, including heartburn and reflux (Table 3).
The pattern and magnitude of associations between
BMI and OA, OGJA or all adenocarcinomas were simi-
lar in the studies with GERD data available compared
with those of all participants (data not shown). A his-
tory of GERD symptoms did not materially alter the
patterns and magnitude of associations between BMI
and cancer. Among individuals with a history of GERD
symptoms, overweight status was associated with an
50% increase in OA risk relative to BMI <25. Risk
increased linearly with increasing BMI to 42-fold in
individuals with BMI 30–34.9 (OR 2.21, 95% CI 1.44–
3.39) and 5-fold in individuals with BMI 35–39.9 (OR
5.84, 95% CI 2.72–12.55). A similar pattern and mag-
nitude of association were also observed among indi-
viduals with no history of GERD symptoms. The
pattern of association in GERD-stratified analyses
was similar for OGJA and the combined grouping of
all adenocarcinomas, although the magnitude of asso-
ciation was somewhat stronger in the BMI–OA than
the BMI–OGJA analyses.
To determine whether gender was an effect modifier
of the observed associations between the exposure,
BMI and the outcome OA/OGJA, we conducted ana-
lyses stratified by gender (Table 4). Compared with
men in the category BMI <25, those with BMI 25–
29.9 were at greater than 60% increased risk of OA
(OR 1.63, 95% CI 1.32–2.00), a risk that increased
linearly with increasing BMI to 44-fold (OR 4.47,
95% CI 2.42–8.26) in men with BMI 540. These pat-
terns of association were similar for OGJA and the
combined group of all adenocarcinomas for men,
although, again, associations were strongest for OA.
This pattern of association between BMI and OA, and
a weaker association with OGJA, were also observed
among women (Figure 1).
To explore the relationships between BMI and OA/
OGJA in men and women further, and the lack of
attenuation of the magnitude of the association in
individuals with symptomatic GERD (heartburn and
reflux), we stratified the spline models by gender
and GERD. The relationship between increasing BMI
and cancer risk was similar for men and women who
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reported symptomatic GERD (Supplementary
Figure S1, available as Supplementary data at IJE
online). Conversely, the relationship appeared attenu-
ated in women compared with the relationship
observed in men with no GERD symptoms
(Supplementary Figure S2, available as
Supplementary data at IJE online), although the ana-
lysis of women who did not report GERD was based
on just 33 OA cases and 357 control subjects.
In analyses testing for interaction (synergism,
departure from additivity), we found evidence for
synergism between BMI and GERD with respect to
OA risk (Table 5). Compared with the referent of no
GERD symptoms and low BMI (<27.5), the OR for
GERD symptoms and low BMI was 2.28 (1.83–2.84),
for no GERD symptoms and high BMI (527.5) was
1.26 (0.91–1.74) and for GERD and high BMI was
3.18 (2.45–4.13). The excess risk attributable to the
synergistic interaction of GERD and high BMI was
estimated to be 0.64 (0.12–1.17), with an AP of OA
due to interaction of 0.20 (0.05–0.35).
Discussion
In this large consortial analysis, we report strong
linear relationships between increasing BMI and the
risk of OA. There was no evidence of effect modifica-
tion when stratified by GERD symptoms, which may
suggest an indirect proinflammatory route of associ-
ation between BMI and OA/OGJA exists, as well as
direct mechanical effects of android fat. There was
putative evidence that gender may modify the rela-
tionship between BMI and OA in individuals without
a history of GERD symptoms, which also may be in-
terpreted as further evidence for an indirect proin-
flammatory route of association emanating from
highly metabolic visceral fat when direct inflamma-
tory routes (GERD) of pathogenesis do not predom-
inate. Lastly, we found evidence for synergistic effects
of BMI and GERD; the risk of cancer in obese indi-
viduals with GERD was significantly higher than pre-
dicted under an additive model.
Our findings of a strong positive dose–response rela-
tionship between BMI and the risk of OA reiterate the
fact that this cancer is the primary malignancy asso-
ciated with obesity.46 We also found similar, although
somewhat weaker, associations for OGJA, and this is
consistent with the hypothesis that OGJA represents a
heterogeneous set of tumours with less clear origin
compared with OA.47 Our results are compatible with
findings from a previous meta-analysis that used pub-
lished ORs from 14 studies,48 6 of them included
here,15,18,26,33,34,49 as well as findings reported by
other studies not included in the present analysis.50–56
Importantly, our study extends these results through
the use of pooled individual participant data and har-
monized variables and statistical models while also
enabling analyses of effect modification and inter-
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that BMI is a risk factor for OA and OGJA, the predom-
inant causal theory of which is that obesity increases
abdominal pressure, which subsequently relaxes the
lower oesophageal sphincter, exposing the lower
oesophagus to gastric acid and increasing the risk of
GERD.20,48,56–58 In support of this hypothesis, the preva-
lence of GERD has been shown to increase with increas-
ing levels of BMI.8,12
The large size of this analysis presented us the unique
opportunity to investigate potential mechanisms of
these associations. When stratified by history of GERD
symptoms, we found no difference in the pattern of as-
sociations between BMI and these adenocarcinomas. In
addition, adjustment for GERD symptoms (ever/never)
did not attenuate the ORs for associations between BMI
and OA/OGJA. These observations do not dispute the
idea that a mechanical effect of BMI that increases the
propensity for GERD and thus the risk for cancer exists,
as we did not adjust for severity or frequency of GERD
symptoms. Moreover, we could not adjust for asymp-
tomatic GERD, as ascertainment of such would obvi-
ously have required all individuals to have undergone
ambulatory 24-h pH-metry. However, what it may sug-
gest is that an indirect, possibly proinflammatory, car-
cinogenic pathway between BMI and OA risk may exist,
in addition to the accepted mechanical pathway of
oesophageal sphincter distortion, increased intra-
gastric pressure and increased risk of hiatal hernia.
Spline models stratified by GERD and gender provided
further evidence for an indirect proinflammatory patho-
genic mechanism of BMI on OA risk—in individuals
without a history of GERD symptoms, increasing BMI
was associated with OA risk in men but not women.
This may suggest that when inflammatory routes of
Table 3 Adjusted odds ratios and 95% confidence intervals for the association between body mass index and risk of











(n) OR 95% CI I2
Oesophageal adenocarcinoma
<25.0 614 94 Referent 705 180 Referent
25.0–29.9 532 95 1.12 0.80–1.58 0 739 282 1.48 1.07–2.05 40
30.0–34.9 136 37 1.85 0.91–3.73 48 224 129 2.21 1.44–3.39 37
35.0–39.9 47 15 2.08 1.00–4.30 0 62 36 2.95 1.15–7.59 49
540 10 4 6.45 a 1.60–25.99 100 20 18 5.84 2.72–12.55 0
Continuous 1341 246 1.07 1.03–1.11 0 1750 645 1.08 1.03–1.14 71
Oesophagogastric junctional adenocarcinoma
<25.0 614 128 Referent 705 172 Referent
25.0–29.9 532 136 1.22 0.77–1.95 56 739 239 1.16 0.87–1.56 24
30.0–34.9 136 54 2.08 1.36–3.19 0 224 116 1.91 1.4–2.6 0
35.0–39.9 47 14 1.49 0.74–2.98 0 62 40 3.65 1.58–8.46 50
540 12 4 3.20 b 0.89–11.52 0 20 11 2.64 1.16–5.99 0
Continuous 1341 337 1.06 1.03–1.09 0 1750 578 1.07 1.04–1.09 0
All adenocarcinomas
<25.0 614 222 Referent 705 352 Referent
25.0–29.9 532 231 1.20 0.92–1.58 17 739 521 1.33 1.02–1.74 44
30.0–34.9 136 91 1.88 1.32–2.67 0 224 245 2.09 1.58–2.77 13
35.0–39.9 47 29 1.68 0.97–2.93 0 62 76 2.98 1.5–5.93 45
540 12 8 3.74 b 1.33–10.54 0 20 29 4.23 2.21–8.09 0
Continuous 1341 583 1.06 1.04–1.09 0 1750 1223 1.08 1.05–1.11 54
Results were adjusted for age (categorical: <50, 50–59, 60–69, 570 years), gender, pack-years of smoking (categorical: <15, 15 to
<30, 30 to <45, 545), education (study-specific) and other study-specific adjustment variables (e.g. study centre, where applic-
able). Summary odds ratios and 95% confidence intervals were obtained from random-effects meta-analytic models. The four
studies that had heartburn and reflux information available were included in these analyses.
aOnly one of the four studies with heartburn and reflux data was able to contribute a study-specific odds ratio to this summary estimate.
bOnly two of the four studies with heartburn and reflux data were able to contribute a study-specific odds ratio to this summary
estimate.
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associations are not saturated by the direct effects of
GERD, the indirect effect can be detected. Such may
be detectable in men, but not women, given the fact
that android fat patterning, with highly metabolic vis-
ceral adipose tissue,20 is common in men relative to the
preferred gynoid fat patterning, with a much lower
metabolic rate, of women.21,22 Obesity-related hor-
mones may induce oesophageal inflammatory damage,
promoting proliferation and malignant transform-
ation.24,59,60 Although we lack central adiposity metrics
to test the theory directly, the evidence we present is
provocative. However, our findings do not preclude
the possibility of collider-stratification bias61 resulting
from the more complex and possibly less direct relation-
ships among obesity, GERD and OA/OGJA. This could
occur if the relationship between GERD and BMI is
mediated by a higher BMI giving way to increased se-
verity and/or duration of GERD, in addition to the pre-
viously posited metabolic carcinogenic effects that a
higher BMI may confer.8,12,14,20,24,30,57–66 In addition,
it should be noted that our findings contrast with
those of at least four previous studies15,19,56,67 that
found stronger associations between BMI and OA/
OGJA in individuals with a history of GERD symptoms,
with the magnitude of the association increasing with
increasing duration and severity of symptoms.67
However, these studies, some of which are included in
the current analyses, suffered small sample sizes, rais-
ing the possibility that inconsistent findings could be
attributed, at least in part, to unstable risk estimates.
Lastly, and supporting the idea of direct mechanical
(distortion of the lower oesophageal sphincter,
increased intra-gastric pressure, increased risk of her-
niation) and indirect metabolic effects on OA risk, was
the observation of synergism between BMI and GERD
symptoms, with an excess risk attributable to synergis-
tic interaction of 0.64 (0.12–1.17). Such interaction was
previously suggested in a paper by Whiteman et al in an
analysis of one of the studies included in this pooled
analysis presented herein.19 As a whole, the evidence
we present advocates for at least two pathways through
which increased BMI can modify OA risk, which may
also be related to the large gender disparity of these
malignancies,6 given gender differences in adipose pat-
terning. Although the stratified models suggest that the
BMI–OA/OGJA relationships may vary by gender in
some BMI categories, with stronger estimates observed
in overweight and obese men, relative to equivalent es-
timates in women, it is important to keep in mind that,
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Figure 1 Restricted cubic spline models of the relationship between body mass index and adenocarcinomas of the
oesophagus and oesophagogastric junction. (a) Oesophageal adenocarcinoma in men. (b) Oesophageal adenocarcinoma in
women. (c) Oesophagogastric junction adenocarcinoma in men. (d) Oesophagogastric junction adenocarcinoma in women.
Plots are restricted to body mass indexes 18.5–45 and odds ratios 0.25–5 for clarity and consistency
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women available for analysis was limited. These limita-
tions are also applicable to a previous meta-analysis48
and three other published studies68–70 that have made
similar observations of differences by gender.6,20–22
Several limitations of this study should be considered
when interpreting our findings. First, none of the stu-
dies included in these analyses collected data on fat dis-
tribution, including body shape, and few collected waist
circumference at different ages during adulthood.
Consequently, fat distribution could not be evaluated
in our analyses. Future studies should identify and
use improved measures of central obesity and other
measures of the body habitus, including those that
could be retrospectively documented.21,71 We have pro-
posed that one of many ways this could be achieved is by
retrospectively querying study participants about life-
course changes in clothing sizes, particularly trouser
waist size, at least for men, focusing on changes in
adulthood.21 Results from two of three studies that eval-
uated waist circumference and BMI in relation to
OA19,26,72 suggest that central obesity is a risk factor
for OA, and a study of Barrett’s oesophagus, an OA pre-
cursor, suggests visceral fat may influence risk inde-
pendent of BMI.73
A second potential limitation of our study is that the
study-specific analyses are not adjusted for dietary
intake, primarily because of differing ways these
data were collected across studies. However, strong
associations between BMI and OA/OGJA have been
reported, regardless of whether adjustments are
made for dietary intake.15,74
A third limitation is that our pooled analysis pre-
dominantly consists of case–control studies that lack
the ability to determine the sequence of events be-
tween obesity and OA/OGJA, as BMI ascertainment
among these studies was limited to 51 years before
interview. However, restricting our analyses to indi-
viduals with a BMI 418.5 did not alter our findings.
Moreover, the association between BMI and OA/OGJA
was also found in the two prospective cohort studies.
Furthermore, such differential recall in case–control
studies would attenuate the magnitude of the risk
for the association between BMI and OA/OGJA, thus
assuaging any concerns that our findings are due to
underestimates of past body weight in patients. Also
related to the timing of case ascertainment relative to
cancer onset is the potential limitation that data for
this pooled analysis include case accrual over a
25-year period (1964–2006), during which time
there have been rapid increases in the prevalence of
obesity in all countries from which the included stu-
dies derive. However, we found no evidence of effects
by calendar period, by visual inspection of forest plots
and meta-regression of mid-year of recruitment.
In summary, this consortial analysis of pooled indi-
vidual participant data has provided evidence that
increasing BMI is associated with an increasing risk
of OA and OGJA, and that these relationships are
similar in those with and without a history of
GERD symptoms. In addition, we provide tentative
evidence for effect modification by gender in those
without GERD symptoms and, lastly, evidence of syn-
ergistic interactions between BMI and GERD. Future
studies should focus on elucidating the mechanisms
that underlie these observations, specifically the
multifaceted effects of obesity on the risk of OA.












Cigarette smoking 0.22 (0.30, 0.73) 0.07 (0.09, 0.22) 1.11 (0.87, 1.40)
Alcohol 0.05 (0.30, 0.40) 0.04 (0.25, 0.34) 1.31 (0.12, 13.74)
H. pylori (negative) 0.06 (0.77, 0.89) 0.03 (0.42, 0.49) 1.08 (0.37, 3.20)
Heartburn 0.44 (0.16, 1.04) 0.18 (0.04, 0.39) 1.42 (0.89, 2.26)
Reflux 0.14 (0.31, 0.58) 0.08 (0.16, 0.32) 1.20 (0.64, 2.28)
Heartburn or refluxa 0.64 (0.12, 1.17) 0.20 (0.05, 0.35) 1.42 (1.04, 1.94)
OGJA vs controls
Cigarette smoking 0.25 (0.28, 0.78) 0.08 (0.08, 0.23) 1.12 (0.88, 1.44)
Alcohol 0.02 (0.30, 0.33) 0.02 (0.36, 0.40) 0.90 (0.16, 4.97)
H. pylori (negative) 0.37 (0.97, 0.22) 0.44 (1.18, 0.30)
Heartburn 0.05 (0.34, 0.45) 0.04 (0.22, 0.29) 1.12 (0.48, 2.58)
Reflux 0.29 (0.01, 0.58) 0.25 (0.00, 0.50)
Heartburn or reflux 0.30 (0.01, 0.60) 0.20 (0.00, 0.40) 2.51 (0.42, 14.98)
AP¼ attributable proportion due to interaction; ICR¼ interaction contrast ratio; OR¼ odds ratio; S¼ synergy index.
aThe excess risk attributable to the synergistic interaction of heartburn or reflux and high BMI ICR, attributable proportion (AP) of OA.
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KEY MESSAGES
 BMI is directly associated with OA risk in both men and women and in those with and without
GERD symptoms.
 Findings suggest an indirect proinflammatory route of association between BMI and OA exists, as
well as direct mechanical effects of android fat.
 Effects of BMI and GERD symptoms on OA risk may be synergistic.
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